Landscapes / Targets
BET
12 drugs act on BET, in 42 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs12
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Amyloid-beta protofibril antibody |
Eisai +1 · Public BIIB |
Approved | 3 Dec 2026soonPhase 2 trial completes | ||
| Next date | 3 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Early Alzheimer's Disease, Preclinical Alzheimer's Disease and 2 more | ||||
| Open drug page | |||||
Thyroid hormone receptor beta (THR-β) agonist |
Madrigal Pharmaceuticals · Public MDGL |
Approved | Dec 2026Phase 3 trial completes | ||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH - Nonalcoholic Steatohepatitis and 5 more | ||||
| Open drug page | |||||
Amyloid-beta antibody (pyroglutamate amyloid beta in plaques) |
Eli Lilly · Public LLY |
Approved | Nov 2027Phase 3 trial completes | ||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Alzheimer Disease, Dementia and 13 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 22 Nov 2026soonPhase 1/2 trial completes | |||
| Next date | 22 Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Kidney Failure, Chronic, Post-Acute COVID-19 Syndrome | ||||
| Open drug page | |||||
GARP/TGF-beta antibody |
AbbVie · Public ABBV |
Phase 2/3 | Nov 2026soonPhase 2 trial completes | ||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Advanced Solid Tumors Cancer and 2 more | ||||
| Open drug page | |||||
Amyloid-beta antibody with a transferrin receptor brain shuttle |
Roche · Public ROG.SW |
Phase 3 | 31 Jul 2027Phase 1/2 trial completes | ||
| Next date | 31 Jul 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Alzheimers Disease, Alzheimer's Disease | ||||
| Open drug page | |||||
Integrin beta-6-targeted antibody-drug conjugate |
Pfizer · Public PFE |
Phase 3 | 5 Sep 2028Phase 3 trial completes | ||
| Next date | 5 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung and 14 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Myelofibrosis | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | mCRPC, Metastatic Castration-Resistant Prostate Cancer | ||||
| Open drug page | |||||
THR-beta agonist unconfirmed |
Phase 2 | 15 Sep 2027Phase 2 trial completes | |||
| How it works | Acts like thyroid hormone | ||||
| Next date | 15 Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Metabolic Dysfunction-associated Steatohepatitis, Adult Obesity and 3 more | ||||
| Open drug page | |||||
— |
AbbVie · Public ABBV |
Phase 1 | Jan 2027Phase 1 trial completes | ||
| Next date | Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Myelofibrosis (MF) | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Apr 2027Phase 1 trial completes | |||
| Next date | 30 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Myelofibrosis, Myelodysplastic Syndrome and 5 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 12 of 12 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026